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Abstract This paper describes progress made by the
Criticality Task Team within the ISPE PQLI initiative. It
aims to provide a concise, coherent, and universal approach
for determining criticality for parameters, material attrib-
utes, conditions, and quality attributes. The work also
clarifies the risk based distinctions governing the assign-
ment of criticality to provide consistency and facilitate the
adoption and implementation of Quality by Design (QbD)
principles in the development of pharmaceutical manufac-
turing processes. The application of the concept of
criticality presented in this paper aligns with the principles
of ICH Q8, Q9 and Q10 guidelines.
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strategy . Critical quality attribute . Critical process
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Introduction
The word “critical” is an adjective and its use to describe
pharmaceutical quality or manufacturing process variables
requires context.1 The use of the word “critical” to define a
process variable, step or attribute can be subjective, relying
on individual assessment of relative risk, based on empirical
knowledge, direct experience or data. Therefore, its meaning
is neither universal nor definitive. In fact, industry concerns
regarding the regulatory implications of labeling a process
variable, attribute or step as “critical” have produced a
variety of cautiously crafted and detailed definitions for its
use. This position paper was developed and written to
provide a concise, coherent and universal approach for
delineating criticality for process variables, e.g., parameters,
material attributes, conditions, etc., and quality attributes.
The purpose of this position paper is to clarify the risk based
distinctions governing the assignment of criticality to provide
some measure of consistency and facilitate the adoption and
implementation of Quality by Design (QbD) principles in the
development of pharmaceutical manufacturing processes.
The assessment of criticality as it relates to pharmaceu-
tical quality is generally determined as a function of risk.
However a legitimate risk assessment is neither effective
nor confident when made in the absence of product
knowledge or process understanding and experience. The
pharmaceutical industry has traditionally assessed risk,
particularly during development, based predominantly on
empirical knowledge, understanding derived from manu-
facturing experience. The advent of Quality by Design has
shifted the paradigm from a retrospective to a prospective,
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1 Crit·i·cal adj: of essential importance. Several definitions for the
word “critical” exist, each reflective of the word it modifies. The
application of criticality presented in this abstract aligns with
principles articulated in ICH Q8, Q9 and Q10 guidelines.
systematic and risk-based approach to develop process
understanding. The need to prioritize and focus experiments
on meaningful variable interactions, to characterize relevant
design space boundaries and establish appropriate control
strategies warrants a robust definition of criticality.
While a simple unencumbered definition of “critical”
might improve consistency in its application, it would also
limit the continuum of risks ascribed to criticality that
encompasses a myriad of relatively complicated, yet
important, business and quality designations for process
variables and product attributes. Figure 1 provides an
example of one company’s internal approach to define
critical process parameters. The variety of designations
reflects how the pharmaceutical industry characterizes
criticality to coincide with multiple expectations from
quality, regulatory and business stakeholders. In addition,
the degree of criticality as a direct reflection of risk may be
conservative depending on the objective of the assessment.
The ISPE PQLI Criticality Task Team continues to
gather collective experience from industry and regulatory
authorities to understand the significance of criticality and its
application to evaluate variables, process parameters as well as
product and material attributes.2 In general, both industry and
regulatory authorities acknowledge distinctions in the defini-
tion of critical variables particularly where there was
regulatory impact. Nevertheless, several common and consis-
tent technical assumptions have emerged from this feedback:
& Criticality can describe any feature or material attribute,
property or characteristic of a drug substance, compo-
nent, excipient, drug product or device and/or any
process attribute, parameter, condition or factor in the
manufacture of a drug product.
& Criticality Analysis distinguishes non-critical variables
from both known and potentially critical variables while
delineating levels or degrees of risk (e.g. high or low) by
which known and potentially critical sources of variability
which may impact the quality of the product are assessed.
& Critical impact may be attributed to multiple variables
operating in sequence or in concert.
& As a result of a Criticality Analysis, designation of non-
critical and critical categories for process variables and/or
product attributes provides a relative and qualitative
classification of their impact to quality, and by extension
to safety and efficacy3 of the drug product for the patient.
& A control can reduce the level of criticality but it does
not change the potential for severity of harm/impact
even though it may reduce the probability and/or
increase detectability.
& A control that reduces the level of criticality for a
process variable, by definition, becomes a critical
control point /parameter/ (HACCP).
& A few drug product CQAs, such as sterility, will always
be critical. These CQAs may be dosage form specific.
& Criticality Analysis is relevant in development of design
space and design space boundaries and establishing
effective control strategies.
& The Criticality Analysis Decision Tree differentiates
business decisions, categorizes non-critical variables in
accordance with risk and, at the discretion of the
sponsor, provides flexibility to designate levels of
criticality governed by relative levels of risk.
& As attribute or parameter boundaries approach edges of
failure the level of criticality increases with an increase
in the level of risk.
& Process parameters or variables controlled to evaluate
business attributes are not necessarily critical unless
demonstrated to directly or indirectly impact quality of
the drug product.
Delineating criticality is essentially a function of
measured risk assessment as shown in Fig. 2. The
assessment of risk is fundamentally predicated on under-
standing the relationship of process variables to one another
and their collective impact to quality attributes of the
product. A variable that is non-critical is differentiated, or
categorized, from variables that are potentially critical
relative to the severity and probability of risk that variable
poses to safety, efficacy and quality of the product and
harm to the patient. The relative level or degree of risk
these variables pose is assessed relative to the probability of
occurrence and ability to detect failure and impose potential
harm to the product/patient.
The assessment of criticality is not static. Continuous
process improvement is a presumptive expectation of
Quality by Design. Innovations, adjustments, optimization
and modifications warrant reassessment of risk and criti-
cality. Therefore risk management is central to the
delineation of criticality and includes the following ele-
ments as summarized from ICH Q9 [6]:
& Risk Identification — finding what risks exist and/or
might exist — problems and potential problems
& Risk Evaluation— severity, probability and detectability
& Risk Control — detectability, i.e., risk management
versus risk measurement and monitoring
➢Risk Reduction—well grounded science and justifi-
able decision making to the extent necessary to
provide appropriate assurance and high degree of
probability of safety, efficacy and quality
2 The substrate for the preliminary position described herein was
developed through direct engagement of industry representatives and
solicited comments from representatives from FDA, EMEA and
MHLW at various ISPE conferences [1–3].
3 Reference is made to ICH Q8R [4] and ICH Q6A [5] wherein
demonstration of quality is commensurate with reducing the impact to
safety and efficacy of the product for the patient.
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➢Risk Mitigation—development of design space,
controls and/or measurements to demonstrate reduc-
tion in the severity of risk.
➢Risk Acceptance—
✓ Some level of risk may remain
✓ Some level of risk may be appropriate considering
the benefit accrued
✓ Some level of risk may be practicably achievable
✓Acceptance of residual risk in accordance with
benefit for patient
& Risk Communication —
➢‘Customers’ need to know what risks have been
considered, how they have been managed and/or
controlled and what residual risk has been accepted.
➢Risk communication can also be a strategic part of a
risk management program
Based on these functional precepts, the development of a
Criticality Analysis Decision Tree emerged as a relatively
direct, non-prescriptive risk assessment process by which
variables, attributes and parameters may be categorized.
Variables with potential to have direct impact on safety and
efficacy as well as quality are distinguished from those
variables, attributes and parameters that do not have an
impact on safety and efficacy and are generally associated
with business criteria, i.e., variables associated with process
efficiency. This process describes a relatively high level
Criticality Analysis that initially distinguishes potentially
critical from non-critical variables with subsequent provi-
sions to differentiate levels of criticality based on formal
risk assessment through the use of “Risk Filters”. The
Criticality Analysis Decision Tree is presented in Fig. 3.
The criticality decision tree is divided into two decision
classifications to facilitate Criticality Analysis. The top
classification is labeled Foundational and serves as the basis
for subsequent decisions delineating critical from non-critical
variables. In the absence of a modern risk-based quality
system, a traditional specification may serve as the basis for
determining critical and non-critical variables and is typically
demonstrated by empirical, process experience. The decision
to develop a control strategy based on traditional specification
limits without benefit of multivariate analysis is driven by
business needs at the discretion of the sponsor.
Similarly, a decision to proceed with a risk-based,
systematic and prospective approach to pharmaceutical
Fig. 1 Example of designations for criticality
Fig. 2 Fundamental elements of risk assessment
J Pharm Innov (2008) 3:69–78 71
development relies on evaluating risk relative to impact on
safety, efficacy and quality. This categorization differ-
entiates non-critical from potentially critical variables,
parameters and attributes based primarily on the severity
or magnitude of the risk. Subsequently, a variable,
parameter or attribute is assessed to delineate levels of
criticality based on whether the probability and the ability
to detect the risk is low or high. Provisions in this process
suggest the use of a Risk Filter to discriminate levels of risk
once a variable is categorized as potentially critical. The
Risk Filter identifies several examples (by no means
exhaustive) to provide the basis to evaluate relative risk.
The level of criticality labeled “X” allows for classifica-
tion of variables, parameters and attributes for which risk
Fig. 3 Criticality analysis decision tree
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(probability and detectability) has not been definitively
ascertained or is secondary or ancillary to other factors.
Variables, parameters and attributes labeled “X” may
require re-evaluation when making changes to multi-variate
design space. In addition, more than two levels of criticality
may be used to describe the level of risk for variables
labeled “X”.
The Criticality Analysis Decision Tree is applicable to
API, drug product, biological and device processes and
products. The integrity of the risk assessment is predicated
on a robust quality system in alignment with principles
articulated in ICH Q9 and Q10 [7] and dependent on well
developed knowledge space for the manufacturing process.
As process understanding and knowledge increase during
the lifecycle of a product the delineation of criticality serves
as an iterative process to reassess the risk of process
variables and quality attributes.
Detailed Explanation of Criticality Analysis Decision
Tree
The first decision differenti-
ates “ tradit ional” from
“QbD” approaches. The dif-
ference in approaches is in
the depth and quality of
p rocess unders t and ing
achieved and demonstrated.
QbD approaches tend to
establish multi-variate design space boundaries and holistic
control strategies while a traditional approach relies
predominantly on process experience, rigid processing and
reliance on end product testing for control. The differenti-
ation between the two approaches is articulated in ICH Q(8)
R. [4]4 The decision to proceed with a risk-based control
strategy to develop product and process understanding will
align with the QbD approach described in ICH Q(8)R. The
decision to proceed with a “traditional” approach sug- gests




parameters relative to tradi-
tional CQA’s defined by
specifications. Parameters
designated as “critical” war-
rant demonstration of con-
trol confirmed by an appropriate test method based on
process experience.
Where a risk-based control
strategy is developed, catego-
rization of variables as non-
critical or critical can be
delineated by appropriate risk
assessment and experimenta-
tion, i.e., the “QbD approach.”
The “QbD” approach leads to
the following collective expectations:
& Product quality and performance are ensured through
the design of effective and capable, i.e., robust
manufacturing processes
& Product and process specifications are based on a
mechanistic understanding of how formulation and
process factors affect product quality and performance.5
& Continuous product and process improvement
& Relevant regulatory policies and procedures are tailored
to reflect current level of scientific knowledge and
associated risk
& Risk-based regulatory approaches recognize:
➢ the level of scientific understanding of how
formulation and manufacturing process factors
affect product quality and performance
➢ the capability of process control strategies to prevent or
mitigate the risk of producing a poor quality product
Prior knowledge is an appropriate basis for risk
assessment decisions for new and legacy products that
proceed through the “QbD” approach.
The bottom layer of the criticality decision tree process
introduces the risk assessment strategy employed by a QbD
approach to product and process development. This decision
tree can be used to assess the criticality of variables in a
product or process, i.e., attributes and parameters. The blue
decision diamond requesting a response to the question,
“What is the potential for variables to impact quality?”
distinguishes the first “category of criticality” by segregat-
ing variables that do not have an impact on quality and
designating them non-critical.
4 “A more systematic approach to development (also defined as
quality by design) can include, for example, incorporation of prior
knowledge, results of studies using design of experiments, use of
quality risk management, and use of knowledge management (see ICH
Q10) throughout the lifecycle of the product. Such a systematic
approach can enhance the process to achieve quality and help the
regulators to better understand a company’s strategy. Product and
process understanding can be updated with the knowledge gained over
the product lifecycle.”
5 A specification is not synonymous to control strategy. A specifica-
tion is only one element of a control strategy.
J Pharm Innov (2008) 3:69–78 73
Those variables that may have an impact on quality fall
into the second “category of criticality” which can be
subsequently evaluated through appropriate risk assess-
ment, as denoted by the “Risk Filter” into “levels of
criticality” designated as either critical or some intermedi-
ate level “X” defined by the magnitude and attenuation of
severity, probability and detectability of risk.
Attributes6 fall within two major categories, those that are
the measurable properties of a material and those that are the
measurable characteristics of the process used to manufac-
ture a material. Quality Attributes have an impact on patient
safety, efficacy or quality. An attribute should be defined as a
Quality Attribute where precedented pharmaceutical knowl-
edge suggests a link may exist even if a direct, scientifically
demonstrable link has not been made between the attribute
and patient safety, efficacy and/or quality.
Variables or parameters that may have important implica-
tions for business purposes, i.e., reducing costs, optimizing
yield, improving process efficiency, environmental and/or
worker safety, etc., or variables associated with a delivery
device and/or packaging of the drug product. may be assessed
for their level of criticality relative to business criteria.
However these variables are not, by definition, necessarily
critical with regards to safety and/or efficacy and should not
be defined as critical from a regulatory perspective.
Process parameters7 are variables that have either been
demonstrated to have a significant impact on Quality
Attributes of the API and/or drug product or those that
have been demonstrated not to have a significant impact on
the Quality Attributes of the API and/or drug product.
Elements necessary to per-
form a Criticality Analysis,
(i.e., risk assessment tools,
functional relationships to
critical quality attributes,
and the criteria by which a
variable is designated as critical, in combination with other
variables or independently), may be determined from (1)
prior knowledge, (2) results from concerted and prospective
designed (e.g., multi-variate) experimentation and (3)
demonstrated process experience. The quality of a product
as defined in accordance with ICH Q 6A8 is a minimum
standard and is a reflection of the Target Product Profile.
The Target Product Profile describes the quality attributes
of the product for its intended use and administration.
While an assessment of risk is predicated on the established
foundation of a robust quality system as defined in
accordance with ICH Q (10), the primary assessment and
designation of criticality should be made relative to impact
to safety and efficacy of the drug product to the patient
which are dependent on measures of quality as reflected by
its Quality Attributes. Development and establishment of
product Quality Attributes to meet the Target Product
Profile introduces a standard level of quality, the measured
assessment of which will establish critical quality attribute
(CQA) boundaries Awell justified risk assessment identifies
criteria to establish the appropriate and relevant elements of a
control strategy. The quality of a product is measured by the
demonstrated application of that control strategy.
Process parameters are assessed for criticality relative to
their impact on product Quality Attributes. Typically, a vast
parameter-attribute matrix is identified and assessed in
accordance with prior knowledge to establish a level of risk
for each parameter relative to its respective Quality
Attributes. Experiments may be conducted in parts of that
variable space where the functional relationship between
parameters and attributes is not well understood. These
experiments establish functional relationships to describe
that variable space and demonstrate process understanding.
Results from this exercise provide criteria by which an
appropriate risk assessment can be justified. There are at
least two categories of criticality to establish risk, i.e.,
critical and non-critical. When it is demonstrated or
suspected that a variable may influence quality, the level
of risk (High or low) is determined by the application of
tools in the Risk Filter. The Risk Filter is not exhaustive
and many other tools may be used to evaluate impact of
risk and delineate criticality. A process is considered well
understood from the physico-chemical perspective when
& sources of variability are explained
& “Quality Attributes” can be predicted based on key
inputs, e.g., process parameters, material attributes, etc.
& process capability of “Quality Attributes” meets accep-
tance levels
If a variable does not have potential to impact Quality, it
is Non-Critical. If a variable has the potential to impact
Quality, the magnitude of the potential for risk must be
evaluated by application of appropriate measures of risk.
The application of principles
of Quality by Design in the
development of process un-
derstanding is predicated on
risk assessment. Risk assess-
ments provide an evaluation of process variables relative to
their level of expected impact on quality.
6 At·tri·bute n: A quality or characteristic inherent in or ascribed to
someone or something.
7 Pa·ram·e·ter n. One of a set of measurable factors, such as
temperature and pressure, that define a system and determine its
behavior and are varied in an experiment.
8 “The definition of quality is the suitability of either a drug substance
or drug product for its intended use.”
74 J Pharm Innov (2008) 3:69–78
Risk assessment is fundamental to the delineation of
criticality in the evaluation of process dimensions and
development of design space. The principles and several
tools for conducting risk assessments are described in ICH
Q (9).9 Criticality is a function of the probability, severity
and detectablity of a variable’s impact on the quality, in
particular, quality attributes, of a product and the detect-
ability for changes in that variable. In FMEA, the product
of Probability X Severity X Detectability is referred to as
the Risk Priority Number. In general, risk should be
assessed based on cause and effect and relative to the
following criteria:
& Probability — the likelihood of an occurrence.
& Severity — the magnitude of the impact of a
consequence.
& Detectability — the level or ability at which an
occurrence can be measured.
& Sensitivity (optional) — the attenuation of interactions
between multivariate dimensions.
In addition, due consideration should be given to the
following factors that may be used to assess risk:
& There are differences in designation of criticality and
level of risk between API and drug product parameters.
& Critical outcomes may be attributed to multiple varia-
bles operating in concert.
& Control strategy based solely on testing does not make a
CQA or CPP non-critical; it just makes it controlled.
The severity of the risk does not change with an
assurance of control, only the probability of risk is
reduced with an assurance of control.
& Use of descriptive adjectives to define criticality should
include context.
& Several levels of criticality may be used to describe
multiple levels of risk.
& As attribute or parameter boundaries approach edges of
failure the level of criticality increases with the level of
risk.
& Criticality is intended to be revisited and assessed
during product lifecycle.
Attributes, parameters and
other variables that have
either been demonstrated or
based on prior knowledge
known not to have potential
to impact safety and/or effi-
cacy of the product are categorized as Non-Critical. Non-
Critical attributes, parameters and variables do not pose a
risk because they are not functionally related to Critical
Quality Attributes. In accordance with ICH Q (8) R non-
critical quality attributes and process parameters do not
have to be included in descriptions of design space. While
the classification of non-critical variables should be
justified, and where appropriate substantiated by data,
additional scientific or technical evaluations of these
variables are unwarranted.
“X” represents an alternative
designation for attributes,
parameters or variables that
have either been demonstrat-
ed, or based on prior knowl-
edge, suspected to have the
potential to impact the quality of the product, where the level
of risk has been assessed as low. This designation may also be
employed to delineate attributes, parameters or variables:
& that may have an indirect impact on safety and/or
efficacy by themselves or in combination with other
variables,
& where risk is mitigated
& where demonstration of knowledge transfer for non-
critical variables requires additional evaluation.
Attributes, parameters or variables in this category may
be functionally related to CQA’s or other quality attributes.
The potential impact or risk these parameters or attributes
pose is re-evaluated in accordance with relevant changes to
the manufacturing process.
A material or process attri-
bute or parameter that is
categorized as critical has
either been demonstrated or
based on prior knowledge
known to have a direct or indirect impact on patient safety,
therapeutic efficacy, in vivo pharmacokinetic/pharmacody-
namic performance and patient compliance for which
failure to control within demonstrable acceptance criteria
produces an unrecoverable result. A Critical Process
Parameter CPP is a process input that, when varied beyond
a limited range, has a direct and significant influence on a
CQA. A Critical Quality Attribute is a quantifiable property
of an intermediate or final product that is considered critical
for establishing the intended purity, efficacy, and safety of
the product. That is, the property must be within a
predetermined range to ensure final product quality. Risk
is controlled for a CQA by establishing a product
specification for the affected attribute. See ICH Q8
Pharmaceutical Development [8]9 ICH Q (9) Quality Risk Management
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Lifecycle Management — Increased Product/Process
Understanding
During the lifecycle of a product there is a presumption that
an increase in process understanding and product knowledge
derived from continuous improvement and optimization
activities as well as increased manufacturing experience
may require re-assessment of attributes, parameters and other
variables. In accordance with ICH Q9 definition of risk
management the Criticality Analysis Decision Tree should
be used for periodic reassessment. Variables, parameters
and attributes implicated in changes to manufacturing
processes or product criteria should be evaluated relative
to relevant quality attributes. Changes to material or process
attributes or parameters controlled to evaluate business
criteria are not necessarily treated as critical unless there is
a demonstrated link to safety, efficacy and quality of the
drug product. Changes in designation from one level or
category of criticality to another must be demonstrated by
data or increased knowledge, i.e., modeling and improved
interpretation of already existing data etc., and may require
appropriate notification to regulatory authorities.
Throughout the lifecycle of a product, control strategy
should differentiate levels of criticality depending on the
impact to the quality of the drug product as defined by the
relationship of process variables and parameters and
material attributes to quality attributes.
Glossary
1. Attribute - A characteristic or inherent property of feature.
(ASTM E2363-06a)
2. Change Management - A systematic approach to proposing,
evaluating, approving, implementing and reviewing changes.
(ICH Q10 EWG)
3. Continuous Verification - An approach to process validation
in which manufacturing process performance is continuously
monitored and evaluated. (ICH Q9)
4. Control Strategy - A planned (like word ‘planned’) set of
controls, derived from current product and process under-
standing, that assures process performance and product quality.
The controls can include parameters and attributes related to
drug substance and drug product materials and components,
facility and equipment operating conditions, in-process con-
trols, finished product specifications, and the associated
methods and frequency of monitoring and control. (ICH Q10
EWG)
5. Critical (For Small Molecules Only) - Critical describes a
feature or aspect of a raw material, intermediate, process or
product that is generally identified through an assessment of
the extent to which its variation can have impact on the quality
of the drug product, and which therefore requires control to
ensure that the product is of acceptable quality. (ICH Q8R)
v5a. Critical (For Biologics Only) - An input parameter that
must be controlled within a meaningful, narrow range to
ensure that drug substance product Critical Quality Attributes
meet specifications.
6. Critical Process Parameter - A process input that, when
varied beyond a limited range, has a direct and significant
influence on a CQA. (PQRI Robustness Paper)
7. Critical Quality Attribute - A quantifiable property of an
intermediate or final product that is considered critical for
establishing the intended purity, efficacy, and safety of the
product. (ICH Q8R)
8. Design Space - The multidimensional combinations and
interaction of input variables (e.g. material attributes) and
process parameters that have been demonstrated to provide
assurance of quality. Working within the design space is not
considered as a change. Movement out of the design space is
considered to be a change and would normally initiate a
regulatory post-approval change process. Design space is
proposed by the applicant and is subject to regulatory
assessment and approval. (ICH Q8)
9. Design of Experiments (DoE) - The arrangement in which
an experimental program is to be conducted, and the selection
of the levels (versions) of one or more factors or factor
combinations to be included in the experiment.
9a. Formal Experimental Design - A structured, organized
method for determining the relationship between factors
affecting a process and the output of that process. Also known
as “Design of Experiments”. (ICH Q8)
10. Detectability - The ability to discover or determine the
existence, presence, or fact of a hazard. (ICH Q9)
11. Edge of Failure - the boundary to a variable or parameter,
beyond which the relevant quality attributes or specification
cannot be met. (ICH Q8R)
12. Innovation - The introduction of new technologies or
methodologies to pharmaceutical development and manufac-
turing. (ICH Q10 EWG)
13. Harm - Damage to health, including the damage that can
occur from loss of product quality or availability.
14. “X” Key - There is managed risk relative to impacting the
safety or efficacy of a product; well controlled.
15. Key Process Parameter (KPP) (For Small Molecules
Only) - Process parameters that may impact a critical quality
attribute. In contrast to a critical process parameter, a key
process parameter has a reduced risk of impacting the safety
or efficacy of the product, even though there is a relationship
to a critical quality attribute. The risk of failure is mitigated by
applying a robust proactive control strategy through internal
quality management system to reduce the natural variability of
the parameter in question. Operating ranges for key process
parameters may be filed as regulatory commitments.
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15a. Key Process Parameter (KPP) (For Biologics Only) - An
adjustable parameter (variable) of the process that, when
maintained within a narrow range, ensures optimum process
performance. A key process parameter does not affect critical
product quality attributes.
16. Knowledge Management - Systematic approach to
collecting, analyzing, storing, and disseminating information
related to products, processes and components. (ICH Q10
EWG)
17. Lifecycle - All phases in the life of a product from the
initial development through marketing until the product’s
discontinuation. Synonymous with Product Lifecycle. (ICH
Q8)
18. Non-Critical - There is a negligible risk of impacting the
safety or efficacy of a product. Syn: Regulatory Insignificant.
19. Non-Critical Process Parameter (For Small Molecules
Only) - A process parameter that has a negligible risk of
impacting the safety or efficacy of a product. It impacts Non-
Critical Quality Attributes which are not related to the safety
or efficacy of a product. Non-Critical Process Parameters are
managed only by internal quality and change control systems.
19a. Non-Critical Process Parameter (For Biologics Only) -
All input parameters that fall outside of the definition for
critical process parameters are non-critical. Non-critical
process parameters may be further subdivided into Key and
Non-Key process parameters, in cases where process perfor-
mance impact is demonstrated.
20. Non-Critical Quality Attribute - A quality attribute that
has a low risk of impacting the safety or efficacy of a product.
Non-Critical Quality Attributes are managed only by internal
quality and change control systems.
21. Non-Key Process Parameter (non-KPP) (For Biologics
Only) - An input parameter that has been demonstrated to be
easily controlled or has a wide acceptable limit.
22. Normal Operating Range (NOR) - A defined range,
within the Proven Acceptable Range, specified in the
manufacturing instructions as the target and range at which
a process parameter is controlled, while producing unit
operation material or final product meeting release criteria
and Critical Quality Attributes. (PQRI Robustness Paper)
23. Parameter - A measurable or quantifiable characteristic of
a system or process. (ASTM E2363-06a)
24. Pharmaceutical Quality System - Management system to
direct and control a pharmaceutical company with regard to
quality. (ICH Q10 EWG based upon ISO 9000-2005)
25. Process Analytical Technologies (PAT) - A system for
designing, analyzing, and controlling manufacturing through
timely measurements (i.e., during processing) of critical
quality and performance attributes of raw and in-process
materials and processes with the goal of assuring final
product quality. (ICH Q8, FDA PAT Guidance; ASTM
E2363-06a, PQRI Robustness Paper, and EU definition)
26. Process Parameter - A process variable (e.g., temperature,
compression force) that can be assigned values to be used as
control levels or operating limits. (Pfizer Quality Standard
definition)
27. Proven Acceptable Range - A characterized range at
which a process parameter may be operated within, while
producing unit operation material or final product meeting
release criteria and Critical Quality Attributes. (PQRI
Robustness Paper)
28. Process Robustness - Ability of a process to tolerate
variability of materials and changes of the process and
equipment without negative impact on quality. (ICH Q8)
29. Quality - The suitability of either a drug substance or drug
product for its intended use. This term includes such
attributes as the identity, strength, and purity (ICH Q8)
30. Quality Attribute - A physical, chemical, or micro-
biological property or characteristic that directly or indirectly
relates to pre-defined product quality (safety, identity,
strength, purity, and marketability of the product). (GPB
Critical Process Parameters: Glossary of Associated Terms,
DRAFT 05Jan’05, GAA)
31. Quality by Design - A systematic approach to develop-
ment that begins with predefined objectives and emphasizes
product and process understanding based on sound science
and quality risk management. (ICH Q8R)
32. Quality Risk Management - A systematic process for the
assessment, control, communication and review of risks to
the quality of the drug (medicinal) product across the product
lifecycle. (ICH Q9)
33. Quality System - The sum of all aspects of a system that
implements quality policy and ensures that quality objectives
are met. (ICH Q9)
34. Real Time Release - Real time release is an outcome of a
control strategy in which product quality is assured for batch
release through a combination of process information and
input or in-process material attribute measurements during
manufacturing in lieu of traditional off-line, end-product
testing. (ICH Q8R)
35. Redefinition of Design Space - A redefinition of design
space occurs when a manufacturing process fundamentally
changes. For example, a change from wet granulation to dry
granulation would require a redefinition of design space since
the original process, on which the design space was based, no
longer exists. A redefinition of the design space does not
include an increase of knowledge around an existing process.
For example, a reclassification of a parameter from CPP to
KPP as a result of increased process knowledge is not a
redefinition of design space since the subject process has not
changed.
36. Requirements - The explicit or implicit needs or expect-
ations of the patients or their surrogates (e.g., health care
professionals, regulators and legislators). In this document,
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“requirements” refers not only to statutory, legislative, or
regulatory requirements, but also to such needs and expect-
ations. (ICH Q9)
37. Risk - The combination of the probability of occurrence
of harm and the severity of that harm. (ICH Q9)
38. Risk Acceptance - The decision to accept risk. (ICH Q9)
39. Risk Analysis - The estimation of the risk associated with
the identified hazards. (ICH Q9)
40. Risk Assessment - A systematic process of organizing
information to support a risk decision to be made within a risk
management process. It consists of the identification of
hazards and the analysis and evaluation of risks associated
with exposure to those hazards. (ICH Q9)
41. Risk Communication - The sharing of information about
risk and risk management between the decision maker and
other stakeholders. (ICH Q9)
42. Risk Control - Actions implementing risk management
decisions. (ICH Q9)
43. Risk Evaluation - The comparison of the estimated risk to
given risk criteria using a quantitative or qualitative scale to
determine the significance of the risk. (ICH Q9)
44. Risk Identification - The systematic use of information to
identify potential sources of harm (hazards) referring to the
risk question or problem description. (ICH Q9)
45. Risk Management - The systematic application of quality
management policies, procedures, and practices to the tasks
of assessing, controlling, communicating and reviewing risk.
(ICH Q9)
46. Risk Reduction - Actions taken to lessen the probability
of occurrence of harm and the severity of that harm. (ICHQ9)
47. Risk Review - Review or monitoring of output/results
of the risk management process considering (if appropriate)
new knowledge and experience about the risk. (ICH Q9)
48. Robustness - The ability of a product/process to
demonstrate acceptable quality and performance while
tolerating variability in inputs. (PQRI Robustness Paper)
49. Stakeholder - Any individual, group or organization that
can affect, be affected by, or perceive itself to be affected by a
risk. Decision makers might also be stakeholders. For the
purposes of this guideline, the primary stakeholders are the
patient, healthcare professional, regulatory authority, and
industry. (ICH Q9)
50. Trend - Tabulation or graphical plot of actual data used to
determine a tendency or drift in conditions or performance.
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